3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Plasma cell
3
Breast
2
Tumor-Agnostic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Conditions
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
1
Interventions
Carboplatin
10
Cisplatin
7
Pemetrexed
6
Vincristine
5
Nivolumab
5
Etoposide
4
Topotecan
3
Specimen Handling
3
Ipilimumab
3
Injections
3
Doxorubicin
3
Talc
2
Radiotherapy
2
Paclitaxel
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Filgrastim
2
Drug Therapy
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
sintilimab
1
ranpirnase
1
raltitrexed
1
pertuzumab
1
pembrolizumab
1
onartuzumab
1
iniparib
1
durvalumab
1
dostarlimab
1
crofelemer
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Olanzapine
×
Other solid neoplasm
×
Clear all
NCT04536558
2020-09-02
OFFER
Sun Yat-sen University
Phase 3
Unknown
352 enrolled